Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 6 | 2019 | 220 | 2.190 |
Why?
|
| Dermatology | 6 | 2016 | 157 | 1.550 |
Why?
|
| Nevus, Pigmented | 3 | 2018 | 6 | 1.450 |
Why?
|
| Melanoma | 3 | 2019 | 166 | 1.380 |
Why?
|
| Cosmetic Techniques | 3 | 2014 | 11 | 1.230 |
Why?
|
| Skin Diseases | 4 | 2016 | 135 | 1.190 |
Why?
|
| Psoriasis | 4 | 2018 | 355 | 0.960 |
Why?
|
| Skin Aging | 2 | 2014 | 9 | 0.840 |
Why?
|
| Ambulatory Care | 3 | 2014 | 112 | 0.790 |
Why?
|
| Specialties, Surgical | 2 | 2013 | 27 | 0.790 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2019 | 90 | 0.760 |
Why?
|
| Humans | 36 | 2020 | 32282 | 0.700 |
Why?
|
| Dermatologic Agents | 2 | 2016 | 233 | 0.690 |
Why?
|
| Biological Therapy | 3 | 2018 | 18 | 0.650 |
Why?
|
| Scalp | 2 | 2020 | 35 | 0.630 |
Why?
|
| Skin | 2 | 2019 | 212 | 0.610 |
Why?
|
| Health Care Surveys | 4 | 2014 | 184 | 0.600 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2019 | 7 | 0.590 |
Why?
|
| Oxyphil Cells | 1 | 2018 | 2 | 0.580 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 1 | 2018 | 4 | 0.580 |
Why?
|
| Metaplasia | 1 | 2018 | 20 | 0.580 |
Why?
|
| Transient Receptor Potential Channels | 1 | 2017 | 4 | 0.540 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2018 | 12 | 0.540 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2018 | 28 | 0.540 |
Why?
|
| Dermoscopy | 2 | 2020 | 12 | 0.530 |
Why?
|
| Neutrophils | 1 | 2018 | 120 | 0.520 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 140 | 0.510 |
Why?
|
| Rosacea | 1 | 2017 | 46 | 0.500 |
Why?
|
| Surgery, Plastic | 2 | 2013 | 29 | 0.500 |
Why?
|
| Skin Care | 1 | 2016 | 12 | 0.480 |
Why?
|
| Hair | 1 | 2016 | 27 | 0.480 |
Why?
|
| Female | 19 | 2020 | 19945 | 0.470 |
Why?
|
| United States | 9 | 2018 | 4072 | 0.460 |
Why?
|
| Biological Factors | 1 | 2015 | 10 | 0.450 |
Why?
|
| Arthritis, Psoriatic | 1 | 2015 | 24 | 0.450 |
Why?
|
| Dermatitis, Atopic | 1 | 2017 | 103 | 0.440 |
Why?
|
| Mycosis Fungoides | 1 | 2014 | 12 | 0.440 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 77 | 0.440 |
Why?
|
| Warts | 1 | 2014 | 3 | 0.430 |
Why?
|
| Aminoquinolines | 1 | 2014 | 18 | 0.430 |
Why?
|
| Inflammation | 1 | 2018 | 506 | 0.430 |
Why?
|
| Antineoplastic Agents | 4 | 2020 | 595 | 0.430 |
Why?
|
| Antigens, CD | 1 | 2014 | 97 | 0.420 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2014 | 2 | 0.420 |
Why?
|
| Medication Adherence | 1 | 2016 | 160 | 0.420 |
Why?
|
| Adjuvants, Immunologic | 1 | 2014 | 61 | 0.420 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2014 | 19 | 0.410 |
Why?
|
| Foreign-Body Reaction | 1 | 2013 | 4 | 0.410 |
Why?
|
| Mass Screening | 1 | 2015 | 256 | 0.380 |
Why?
|
| Biocompatible Materials | 1 | 2014 | 240 | 0.380 |
Why?
|
| Health Care Costs | 1 | 2013 | 122 | 0.370 |
Why?
|
| Hospital Costs | 1 | 2012 | 48 | 0.360 |
Why?
|
| Male | 14 | 2019 | 19441 | 0.360 |
Why?
|
| Vitamin D | 1 | 2013 | 186 | 0.360 |
Why?
|
| Benchmarking | 1 | 2012 | 24 | 0.360 |
Why?
|
| African Americans | 2 | 2016 | 1335 | 0.350 |
Why?
|
| Exercise | 1 | 2016 | 603 | 0.350 |
Why?
|
| Burns | 1 | 2012 | 102 | 0.340 |
Why?
|
| Diagnosis, Differential | 5 | 2019 | 504 | 0.340 |
Why?
|
| Administration, Cutaneous | 3 | 2016 | 116 | 0.320 |
Why?
|
| Adult | 9 | 2020 | 9259 | 0.320 |
Why?
|
| Delivery of Health Care | 1 | 2012 | 167 | 0.310 |
Why?
|
| Faculty, Medical | 1 | 2010 | 76 | 0.310 |
Why?
|
| Middle Aged | 10 | 2020 | 11851 | 0.310 |
Why?
|
| Orthopedics | 1 | 2010 | 93 | 0.300 |
Why?
|
| Aged | 8 | 2020 | 10263 | 0.300 |
Why?
|
| Continental Population Groups | 1 | 2010 | 228 | 0.290 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 545 | 0.290 |
Why?
|
| Students, Medical | 1 | 2010 | 126 | 0.290 |
Why?
|
| Biopsy | 3 | 2019 | 252 | 0.290 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 461 | 0.270 |
Why?
|
| Internship and Residency | 1 | 2010 | 319 | 0.250 |
Why?
|
| Immunocompromised Host | 2 | 2018 | 53 | 0.240 |
Why?
|
| Disease Management | 2 | 2019 | 129 | 0.240 |
Why?
|
| Polymethyl Methacrylate | 2 | 2014 | 11 | 0.210 |
Why?
|
| Polymers | 2 | 2014 | 66 | 0.200 |
Why?
|
| Lactic Acid | 2 | 2014 | 56 | 0.200 |
Why?
|
| Polyesters | 2 | 2014 | 76 | 0.200 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 762 | 0.190 |
Why?
|
| Immunologic Factors | 2 | 2019 | 53 | 0.180 |
Why?
|
| Treatment Outcome | 4 | 2019 | 3416 | 0.170 |
Why?
|
| Young Adult | 2 | 2018 | 2649 | 0.160 |
Why?
|
| Scalp Dermatoses | 1 | 2020 | 18 | 0.160 |
Why?
|
| Glucocorticoids | 3 | 2019 | 146 | 0.160 |
Why?
|
| Sex Factors | 2 | 2013 | 655 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 324 | 0.160 |
Why?
|
| Alopecia | 1 | 2020 | 29 | 0.160 |
Why?
|
| Tibial Nerve | 1 | 2020 | 19 | 0.160 |
Why?
|
| Taxoids | 1 | 2020 | 50 | 0.150 |
Why?
|
| Dermatofibrosarcoma | 1 | 2019 | 3 | 0.150 |
Why?
|
| Sural Nerve | 1 | 2020 | 25 | 0.150 |
Why?
|
| Sweet Syndrome | 1 | 2019 | 6 | 0.150 |
Why?
|
| Nail Diseases | 1 | 2019 | 5 | 0.150 |
Why?
|
| Mohs Surgery | 1 | 2019 | 16 | 0.150 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2019 | 2 | 0.150 |
Why?
|
| Cellulitis | 1 | 2019 | 12 | 0.150 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2019 | 4 | 0.150 |
Why?
|
| Median Nerve | 1 | 2020 | 50 | 0.150 |
Why?
|
| Streptococcal Infections | 1 | 2019 | 23 | 0.150 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 9 | 0.150 |
Why?
|
| Pityriasis Lichenoides | 1 | 2019 | 4 | 0.150 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2020 | 51 | 0.150 |
Why?
|
| Keratosis | 1 | 2019 | 22 | 0.150 |
Why?
|
| Interleukin-2 | 1 | 2019 | 38 | 0.150 |
Why?
|
| Oncolytic Virotherapy | 1 | 2019 | 16 | 0.150 |
Why?
|
| Plasmapheresis | 1 | 2019 | 11 | 0.150 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 11 | 0.150 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2019 | 5 | 0.150 |
Why?
|
| Interferon-alpha | 1 | 2019 | 68 | 0.150 |
Why?
|
| Drug Eruptions | 1 | 2018 | 9 | 0.140 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 46 | 0.140 |
Why?
|
| Quinolines | 1 | 2018 | 29 | 0.140 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 264 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2018 | 31 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 222 | 0.140 |
Why?
|
| Molluscum Contagiosum | 1 | 2018 | 3 | 0.140 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 42 | 0.140 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2018 | 9 | 0.140 |
Why?
|
| Interleukin-17 | 1 | 2018 | 26 | 0.140 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2018 | 16 | 0.130 |
Why?
|
| Ultraviolet Rays | 1 | 2017 | 48 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 1479 | 0.130 |
Why?
|
| Ultrasonography | 1 | 2020 | 393 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 248 | 0.130 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 2016 | 5 | 0.130 |
Why?
|
| Cytokines | 1 | 2018 | 237 | 0.120 |
Why?
|
| Family Practice | 2 | 2014 | 49 | 0.120 |
Why?
|
| Meat | 1 | 2016 | 16 | 0.120 |
Why?
|
| Cross-Cultural Comparison | 1 | 2016 | 20 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 2 | 2019 | 245 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2016 | 30 | 0.120 |
Why?
|
| Office Visits | 1 | 2016 | 72 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2016 | 137 | 0.120 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 276 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 3900 | 0.110 |
Why?
|
| Pemphigoid, Bullous | 3 | 2019 | 9 | 0.110 |
Why?
|
| Adolescent | 2 | 2013 | 3519 | 0.110 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2014 | 8 | 0.110 |
Why?
|
| Immunocompetence | 1 | 2014 | 12 | 0.110 |
Why?
|
| Durapatite | 1 | 2014 | 9 | 0.110 |
Why?
|
| Injections, Subcutaneous | 1 | 2014 | 36 | 0.110 |
Why?
|
| Face | 1 | 2014 | 29 | 0.110 |
Why?
|
| Hyaluronic Acid | 1 | 2014 | 51 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2240 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 212 | 0.100 |
Why?
|
| General Surgery | 2 | 2014 | 84 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2019 | 1425 | 0.100 |
Why?
|
| Injections | 1 | 2013 | 72 | 0.100 |
Why?
|
| Botulinum Toxins | 1 | 2013 | 30 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 43 | 0.100 |
Why?
|
| Calcitriol | 1 | 2013 | 29 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2013 | 72 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 757 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 120 | 0.100 |
Why?
|
| Betamethasone | 1 | 2013 | 53 | 0.100 |
Why?
|
| Phenotype | 1 | 2014 | 622 | 0.100 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 129 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 191 | 0.090 |
Why?
|
| Drug Therapy | 1 | 2012 | 15 | 0.090 |
Why?
|
| Australia | 1 | 2012 | 35 | 0.090 |
Why?
|
| Bandages | 1 | 2012 | 34 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 395 | 0.090 |
Why?
|
| Fluid Therapy | 1 | 2012 | 25 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 106 | 0.090 |
Why?
|
| Surgical Procedures, Operative | 1 | 2012 | 79 | 0.090 |
Why?
|
| Child | 2 | 2016 | 2435 | 0.090 |
Why?
|
| Length of Stay | 1 | 2012 | 321 | 0.080 |
Why?
|
| Medicine | 1 | 2010 | 36 | 0.080 |
Why?
|
| Asian Americans | 1 | 2010 | 92 | 0.080 |
Why?
|
| Age Factors | 1 | 2013 | 1179 | 0.080 |
Why?
|
| Biopsy, Needle | 2 | 2019 | 95 | 0.070 |
Why?
|
| Fever | 2 | 2019 | 59 | 0.070 |
Why?
|
| Registries | 1 | 2010 | 294 | 0.070 |
Why?
|
| Animals | 2 | 2018 | 8199 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2016 | 3626 | 0.070 |
Why?
|
| Time Factors | 1 | 2013 | 2205 | 0.070 |
Why?
|
| Quality of Life | 1 | 2013 | 964 | 0.070 |
Why?
|
| European Continental Ancestry Group | 1 | 2010 | 1076 | 0.060 |
Why?
|
| Hispanic Americans | 1 | 2010 | 772 | 0.060 |
Why?
|
| Albumins | 1 | 2020 | 42 | 0.040 |
Why?
|
| Ankle | 1 | 2020 | 28 | 0.040 |
Why?
|
| Epidermis | 1 | 2020 | 29 | 0.040 |
Why?
|
| Forearm | 1 | 2020 | 44 | 0.040 |
Why?
|
| Electrodiagnosis | 1 | 2020 | 41 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2020 | 38 | 0.040 |
Why?
|
| Wrist | 1 | 2020 | 44 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 57 | 0.040 |
Why?
|
| Streptococcus | 1 | 2019 | 8 | 0.040 |
Why?
|
| Leg | 1 | 2020 | 67 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2019 | 20 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 18 | 0.040 |
Why?
|
| Neural Conduction | 1 | 2020 | 82 | 0.040 |
Why?
|
| Thigh | 1 | 2019 | 35 | 0.040 |
Why?
|
| Dermatitis Herpetiformis | 1 | 2019 | 1 | 0.040 |
Why?
|
| Epidermolysis Bullosa Acquisita | 1 | 2019 | 1 | 0.040 |
Why?
|
| Pemphigoid Gestationis | 1 | 2019 | 3 | 0.040 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2019 | 3 | 0.040 |
Why?
|
| Fingers | 1 | 2019 | 75 | 0.040 |
Why?
|
| Pemphigus | 1 | 2019 | 8 | 0.040 |
Why?
|
| Acneiform Eruptions | 1 | 2018 | 1 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 33 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2019 | 24 | 0.040 |
Why?
|
| Phototherapy | 1 | 2019 | 47 | 0.040 |
Why?
|
| Methotrexate | 1 | 2019 | 70 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 292 | 0.040 |
Why?
|
| Receptor, erbB-2 | 1 | 2018 | 63 | 0.030 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2018 | 2 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 553 | 0.030 |
Why?
|
| Biofilms | 1 | 2018 | 22 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2018 | 9 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 85 | 0.030 |
Why?
|
| Encephalopathy, Bovine Spongiform | 1 | 2016 | 2 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 853 | 0.030 |
Why?
|
| Cattle | 1 | 2016 | 116 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 444 | 0.030 |
Why?
|
| Pregnancy | 1 | 2019 | 961 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 2316 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2014 | 78 | 0.030 |
Why?
|
| Hospitalization | 1 | 2016 | 475 | 0.030 |
Why?
|
| Infant | 1 | 2016 | 1010 | 0.030 |
Why?
|
| Pediatrics | 1 | 2014 | 158 | 0.020 |
Why?
|
| North Carolina | 1 | 2016 | 1300 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2014 | 330 | 0.020 |
Why?
|